期刊
JOURNAL OF INFECTIOUS DISEASES
卷 215, 期 12, 页码 1883-1887出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix208
关键词
Tuberculosis; Immunotherapy; Denileukin diftitox recombinant fusion protein toxin; Host-directed therapy
资金
- National Institute of Allergy and Infectious Diseases [AI079590, 037856, 036973]
- Howard Hughes Medical Institute
Host-directed therapies that augment host immune effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment. We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculosis (TB) infection and analyzed the cellular composition and bacterial burden in lungs and spleens. These in vivo studies show that denileukin diftitox potentiates standard TB treatment in the mouse model, an effect which may be due to depletion of T-regulatory and myeloid-derived suppressor cells during TB infection. Our results indicate that denileukin diftitox and other suppressor cell-depleting therapies may be useful adjunctive, host-directed therapies for TB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据